Method development for generation of PDX models from rapid autopsy samples for the NCI Patient-Derived Models Repository |
2022 |
AACR |
Genomic characterization of PDX models from rare cancer patients in the NCI Patient-Derived Models Repository |
2022 |
AACR |
Quality control workflows developed for the NCI Patient-Derived Models Repository using low pass whole genome sequencing and whole exome sequencing |
2022 |
AACR |
Comparative single cell transcriptome profiling of BL0293 PDX primary tumors, CTCs, and metastatic sites |
2022 |
AACR |
Patient-derived organoid drug responses corroborate known target-drug interactions for selected anticancer agents |
2022 |
AACR |
Patient-derived models of rare cancers in the National Cancer Institute's Patient-Derived Models Repository (PDMR) |
2021 |
AACR |
Single agent response comparisons in a large-scale, preclinical trial of rare cancer PDXs by the National Cancer Institute's Patient-Derived Models Repository (PDMR) |
2021 |
AACR |
Applications of immunohistochemistry in characterization of patient derived xenograft models |
2021 |
AACR |
Imaging Characterization of NCI Patient Derived Models Repository (PDMR) xenografts |
2021 |
AACR |
Study of tumor heterogeneity and subclonality in primary pancreatic and metastatic sites from rapid autopsy patients in PDMR |
2021 |
AACR |
Quality control efforts in a large-scale, preclinical trial of rare cancer PDXs by the National Cancer Institute’s Patient-Derived Models Repository (PDMR) |
2020 |
AACR |
Patient-derived organoid and cell culture models from the NCI Patient-Derived Models Repository (NCI PDMR) preserve genomic stability and heterogeneity of patient tumor specimens |
2020 |
AACR |
Genomic landscape of acquired uniparental disomy in NCI PDMR patient-derived xenograft models |
2020 |
AACR |
Evaluation of patient-derived cell lines and cancer organoids for the prediction of drug responses in patient-derived xenograft models |
2020 |
AACR |
Integrative analyses of signaling and DNA damage repair pathways in patient-derived xenograft (PDX) models from NCI’s Patient-Derived Models Repository (PDMR) |
2019 |
ASCO |
Comparison of genomic biomarkers identified by the whole exome, RNASeq and whole genome sequencing pipelines developed for the PDMR |
2019 |
AACR |
Xenograft-associated B cell lymphoproliferative disease as a surrogate model to study Epstein-Barr Virus (EBV) driven lymphoma of the elderly |
2019 |
AACR |
Comparison of PDX, PDC, and PDOrg models from the National Cancer Institute's Patient-Derived Models Repository (PDMR) |
2019 |
AACR |
PDX models generated from a patient with metastatic colon adenocarcinoma display both spatial and temporal tumor heterogeneity |
2018 |
AACR |
Xenograft-associated B cell lymphoproliferative disease as a surrogate model to study Epstein-Barr Virus (EBV) driven lymphoma of the elderly |
2018 |
AACR |
The National Cancer Institute’s Patient-Derived Models Repository (PDMR) |
2018 |
AACR |
Assessment of the Genomic Stability and Molecular Landscape of Patient-Derived Xenograft (PDX) Models from NCI’s Patient-Derived Models Repository (PDMR |
2018 |
ASCO |
Establishing a platform for the generation of organoids from diverse tumor types as part of the NCI Patient-Derived Models (PDM) initiative |
2017 |
AACR |
The National Cancer Institute’s Patient-Derived Models Repository (PDMR) |
2017 |
AACR |
NCI's Patient-Derived Models Repository: Generating models from racial and ethnic minorities |
2017 |
AACR-Cancer Health Disparities |
Individual ancestry estimation from whole exome sequencing data in patient-derived xenograft samples |
2017 |
Genome Informatics, CSHL |
Clonal heterogeneity in patient-derived xenografts: The neuroendocrine PDX model BL0479 contains stable clones with epithelial or mesenchymal characteristics and differential drug sensitivities |
2015 |
AACR |
Cell sorting strategies for the isolation of cancer cells and associated fibroblasts from tumor biopsies, surgical resections and patient-derived xenografts |
2015 |
AACR |